Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (461-470 of 869) with videos related to

Pageof 87
Sort By:
Blood|October 13, 2006
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)Dharminder Chauhan, Paola Neri, Mugdha Velankar, et al.
Blood|January 24, 2009
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibitionGiada Bianchi, Laura Oliva, Paolo Cascio, et al.
Leukemia|August 24, 2018
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implicationsYu-Tzu Tai, Liang Lin, Lijie Xing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironmentToshiaki Hayashi, Teru Hideshima, Aaron N Nguyen, et al.
Blood Cancer Journal|November 11, 2018
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingPaul G Richardson, Jesus F San Miguel, Philippe Moreau, et al.
Blood|February 1, 2012
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune functionDouglas W McMillin, Jake Delmore, Joseph M Negri, et al.
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.
Blood|January 18, 2003
Molecular sequelae of histone deacetylase inhibition in human malignant B cellsNicholas Mitsiades, Constantine S Mitsiades, Paul G Richardson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
Management of relapsed and relapsed/refractory multiple myelomaJacob P Laubach, Constantine S Mitsiades, Anuj Mahindra, et al.
Cancers|January 13, 2019
Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in OncogenesisMatthew Ho Zhi Guang, Emma L Kavanagh, Luke Paul Dunne, et al.
Pageof 87

Showing results (461-470 of 869) with videos related to

Sort By:
Pageof 87
Blood|October 13, 2006
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)Dharminder Chauhan, Paola Neri, Mugdha Velankar, et al.
Blood|January 24, 2009
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibitionGiada Bianchi, Laura Oliva, Paolo Cascio, et al.
Leukemia|August 24, 2018
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implicationsYu-Tzu Tai, Liang Lin, Lijie Xing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironmentToshiaki Hayashi, Teru Hideshima, Aaron N Nguyen, et al.
Blood Cancer Journal|November 11, 2018
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingPaul G Richardson, Jesus F San Miguel, Philippe Moreau, et al.
Blood|February 1, 2012
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune functionDouglas W McMillin, Jake Delmore, Joseph M Negri, et al.
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.
Blood|January 18, 2003
Molecular sequelae of histone deacetylase inhibition in human malignant B cellsNicholas Mitsiades, Constantine S Mitsiades, Paul G Richardson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
Management of relapsed and relapsed/refractory multiple myelomaJacob P Laubach, Constantine S Mitsiades, Anuj Mahindra, et al.
Cancers|January 13, 2019
Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in OncogenesisMatthew Ho Zhi Guang, Emma L Kavanagh, Luke Paul Dunne, et al.
Pageof 87